| P50 | author | Seyedmojtaba Seyedmousavi | Q40062294 |
| | Johan Mouton | Q42711138 |
| | Willem Melchers | Q56859383 |
| | Paul E. Verweij | Q70514014 |
| P2860 | cites work | Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis | Q28217179 |
| | Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America | Q28263689 |
| | Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia | Q28284944 |
| | Discovery of a HapE mutation that causes azole resistance in Aspergillus fumigatus through whole genome sequencing and sexual crossing | Q28485433 |
| | Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism | Q30853962 |
| | Side population cells and Bcrp1 expression in lung. | Q33186312 |
| | Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. | Q33613758 |
| | Intracellular concentrations of posaconazole in different compartments of peripheral blood | Q33962775 |
| | Analysis of growth characteristics of filamentous fungi in different nutrient media. | Q33971124 |
| | Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients | Q34108650 |
| | Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis | Q34290034 |
| | Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease | Q34574325 |
| | Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy | Q34754956 |
| | Composite survival index to compare virulence changes in azole-resistant Aspergillus fumigatus clinical isolates | Q34977071 |
| | Aspergillosis. Pathogenesis, clinical manifestations, and therapy | Q35038459 |
| | Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature | Q35666591 |
| | Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults | Q35685548 |
| | Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009. | Q35848799 |
| | Pharmacodynamics of anidulafungin against clinical Aspergillus fumigatus isolates in a nonneutropenic murine model of disseminated aspergillosis. | Q36505281 |
| | Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosis | Q36505539 |
| | Pharmacodynamics and dose-response relationships of liposomal amphotericin B against different azole-resistant Aspergillus fumigatus isolates in a murine model of disseminated aspergillosis | Q36757621 |
| | Interpretation of antibiotic concentration ratios measured in epithelial lining fluid | Q36936597 |
| | Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects | Q37072036 |
| | Intrapulmonary posaconazole penetration at the infection site in an immunosuppressed murine model of invasive pulmonary aspergillosis receiving oral prophylactic regimens. | Q37713035 |
| | Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma | Q37761047 |
| | Assessment of efficacy of antifungals in experimental models of invasive aspergillosis in an era of emerging resistance: the value of real-time quantitative PCR. | Q37926156 |
| | Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents | Q37927017 |
| | The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach | Q37977530 |
| | Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis. | Q38140015 |
| | The role of azoles in the management of azole-resistant aspergillosis: from the bench to the bedside. | Q38234496 |
| | Therapeutic outcome in invasive aspergillosis | Q38970340 |
| | Azole, polyene and echinocandin MIC distributions for wild-type, TR34/L98H and TR46/Y121F/T289A Aspergillus fumigatus isolates in the Netherlands. | Q39115857 |
| | Concentration of antifungal agents within host cell membranes: a new paradigm governing the efficacy of prophylaxis | Q39471624 |
| | Azole-resistant invasive aspergillosis in a patient with acute myeloid leukaemia in Germany. | Q40274784 |
| | Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles | Q41370116 |
| | First reported case of azole-resistant aspergillus fumigatus due to the TR/L98H mutation in Germany | Q42383280 |
| | Understanding antifungal prophylaxis with posaconazole in hematology patients: an evolving bedside to bench story | Q42385111 |
| | Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure | Q42555868 |
| | Azole resistance in Aspergillus: a growing public health menace | Q43607400 |
| | Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles | Q44157648 |
| | Multidrug resistance in Aspergillus fumigatus. | Q44261807 |
| | Multiple-azole-resistant Aspergillus fumigatus osteomyelitis in a patient with chronic granulomatous disease successfully treated with long-term oral posaconazole and surgery. | Q44318186 |
| | Azole-resistant Aspergillus fumigatus due to TR46/Y121F/T289A mutation emerging in Belgium, July 2012. | Q45234796 |
| | Quantitative assessment of epithelial lining fluid in the lung | Q45698958 |
| | Azole-resistant central nervous system aspergillosis. | Q46094844 |
| | Bronchoalveolar lavage. Quantitation of intraalveolar fluid? | Q50786468 |
| | Multi-azole resistance in Aspergillus fumigatus | Q56837308 |
| | Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis | Q56993324 |
| | Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? | Q61546279 |
| | Aspergillosis—and a misleading sensitivity result | Q63914856 |
| | Multiple-Triazole–Resistant Aspergillosis | Q63914862 |
| | Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution | Q68861405 |
| | Invasive aspergillosis in critically ill patients without malignancy | Q80269940 |
| | Simultaneous determination of the azoles voriconazole, posaconazole, isavuconazole, itraconazole and its metabolite hydroxy-itraconazole in human plasma by reversed phase ultra-performance liquid chromatography with ultraviolet detection | Q83453027 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | aspergillosis | Q259626 |
| P1104 | number of pages | 8 | |
| P304 | page(s) | 1487-1494 | |
| P577 | publication date | 2014-12-22 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Posaconazole prophylaxis in experimental azole-resistant invasive pulmonary aspergillosis | |
| P478 | volume | 59 | |